-

Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs

MADISON, Wis.--(BUSINESS WIRE)--Invenra Inc., an innovative leader in bispecific antibody technology, is pleased to announce a strategic collaboration with Catalent, a global Contract Development and Manufacturing Organization (CDMO) specializing in innovative drug development solutions. The collaboration will harness the combined expertise and proprietary technologies of Invenra and Catalent to co-discover novel bispecific antibody-drug conjugates.

Dr. Roland Green, CEO of Invenra, remarks, “We are excited to collaborate with the innovative team at Catalent’s Redwood Bioscience subsidiary. We believe that the combination of Invenra’s B-Body bispecific antibody platform with Catalent's SMARTag® ADC expertise has the potential to unlock synergies and accelerate the development of next-generation cancer therapeutics.”

Both companies share a commitment to developing novel therapeutic solutions with the potential to make a meaningful impact in the lives of patients.

About Invenra Inc:

Driven by our mission to deliver groundbreaking therapies to patients worldwide and a commitment to innovation and excellence, Invenra is a leading bispecific antibody technology company. Our proprietary B-Body® platform offers profound advantages in discovery, manufacturing, and formulation, along with true "Plug & Play" performance, enabling rapid engineering of therapeutics. Our extensive portfolio of wholly owned and partnered molecules includes first and best-in-class bispecifics, making us a pioneer in therapeutic innovation.

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

Industry:

Invenra Inc.

Release Versions
English

Contacts

Invenra Media Contact
Bryan Glaser
Senior Vice President Business Development
Invenra Inc.
608-441-8319
bglaser@invenra.com

More News From Invenra Inc.

Invenra To Feature Cancer Patient Art in Upcoming Antibody Therapy Development Project

MADISON, Wis.--(BUSINESS WIRE)--Invenra, Inc., a biotechnology company pioneering multispecific antibody therapeutics, is requesting cancer patient and survivor artwork, which will be featured in an innovative project linking patient experiences to people doing important cancer research and development. If selected, artists will earn a $1,000 stipend and have their work featured in a one-of-a-kind playing card deck that celebrates the creativity, resilience, and spirit of people whose lives hav...

Invenra Inc. and Xcellon Biologics Announce Collaboration to Advance Bispecific and Trispecific Antibody-Drug Conjugate (ADC) Development

MADISON, Wis, & NORTH BETHESDA, Md.--(BUSINESS WIRE)--Invenra Inc., a U.S.-based biotechnology company pioneering multispecific antibody platform technologies, and Xcellon Biologics, a wholly owned subsidiary of Linden Lake Labs and a U.S.-based contract development and manufacturing organization (CDMO) specializing in antibody–drug conjugates (ADCs) and complex biologics, today announced a strategic collaboration to advance the development of multispecific ADCs. Under the collaboration, Invenr...

Invenra Welcomes Dr. Alan J. Korman to Its Scientific Advisory Board

MADISON, Wis.--(BUSINESS WIRE)--Invenra, a biotechnology company specializing in next-generation multispecific antibody discovery and development, is pleased to announce the appointment of Dr. Alan J. Korman, PhD, FAIO, to its Scientific Advisory Board (SAB). Dr. Korman brings a wealth of experience in immuno-oncology, having played a pivotal role in the development of groundbreaking cancer immunotherapies. Dr. Korman is currently CSO and a member of the Board of Directors of Bluesphere Bio, a...
Back to Newsroom